Douglas Swirsky - Jun 14, 2024 Form 4 Insider Report for Cellectar Biosciences, Inc. (CLRB)

Role
Director
Signature
/s/ Christina Blakley, attorney-in-fact for Douglas Swirsky
Stock symbol
CLRB
Transactions as of
Jun 14, 2024
Transactions value $
$0
Form type
4
Date filed
6/18/2024, 05:01 PM
Previous filing
Mar 19, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLRB Stock option (right to buy) Award $0 +90K $0.00 90K Jun 14, 2024 Common Stock 90K $2.58 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was contingently granted on December 22, 2023, subject to approval by Cellectar's stockholders of Cellectar's amended 2021 Stock Incentive Plan at Cellectar's 2024 Annual Meeting of Stockholders. Such stockholder approval was obtained on June 14, 2024.
F2 This option shall vest in full on December 22, 2024, subject to the reporting person's continued service through the applicable vesting date.